John Hyngstrom,
MD
Languages Spoken: English
Dr. Hyngstrom is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the department of Surgery at the University of Utah. His medical practice is in general surgical oncology with a focus on melanoma and sarcoma, treating patients at the Huntsman Cancer Institute. His research interests include immunotherapy clinical trial development and survivorship issues in cancer patients. He currently serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on improving care for patients with advanced melanoma and other solid tumors. He is co-director of the physician-lead Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI. He also serves as the Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.
Dr. Hyngstrom earned his Bachelor of Arts degree from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from the University of Chicago Pritzker School of Medicine and completed his general surgery residency at the University of Chicago Medical Center. During his residency, he completed a two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. After finishing his general surgery training, Dr. Hyngstrom obtained his fellowship training in general surgical oncology at the University of Texas MD Anderson Cancer Center. Since 2012, he has worked as a faculty surgeon at the University of Utah Huntsman Cancer Institute, and as a contracted surgeon at Intermountain Medical Center.
Clinical Locations
801-587-8808
Fax: (801) 581-6470
Board Certification and Academic Information
| Academic Departments | Surgery
-
Associate Professor (Clinical) |
| Academic Divisions | General Surgery |
| Board Certification | American Board of Surgery |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.7/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 19, 2022
Huntsman Cancer Institute
While I hope to never recommend anyone to a doctor for melanoma, I would absolutely recommend Dr. Hyngstrom and crew.
UofU Patient
October 29, 2022
Huntsman Cancer Institute
I greatly appreciate that Dr. Hyngstrom works to understand the evidence related to cancer treatments, including both effectiveness and limitations, and to help his patients understand their situation and make their treatment decisions wisely.
UofU Patient
October 22, 2022
Huntsman Cancer Institute
Dr. Hyngstrom is amazing and one of the best doctors I've ever had! He explains things to me in a way that I can understand and gives me the assurance and hope I occasionally need. I feel fortunate to be under his watch! Thank you, Dr Hyngstrom!!!
UofU Patient
October 21, 2022
HUNTSMAN CANCER CENTER
He is a 10 for sure
UofU Patient
October 17, 2022
HUNTSMAN CANCER CENTER
Very professional and genuinely concerned about my condition.
UofU Patient
October 17, 2022
HUNTSMAN CANCER CENTER
The care team was wonderful when I finally got to see them. What was awful was the process I had to go through prior to our meeting. I had been to tumor board twice, had a PET and CT scan, brain MRI plus a biopsy all within the last three weeks. Not to mention that I've been going to this clinic for 9 years and I was told over the phone that I might need more scans before I could see Dr. Hystrom This was very hard to take. When you add on to that the over an hour wait in the waiting area, I was quite emotional and came into my appointment feeling like nobody wanted to treat my cancer.
UofU Patient
September 23, 2022
HUNTSMAN CANCER CENTER
Highly recommend the clinic and staff.
UofU Patient
September 18, 2022
HUNTSMAN CANCER CENTER
Great listeners and very kind staff
UofU Patient
September 10, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
September 01, 2022
HUNTSMAN CANCER CENTER
Things were explained fairly well. I just wasn't prepared for my physical appearance after surger.
UofU Patient
August 28, 2022
HUNTSMAN CANCER CENTER
Dr. Hyngstrom is very attentive, thorough and personal. I highly recommend him as a physician. I did not have any questions or concerns as this was a routine annual follow-up visit.
UofU Patient
August 06, 2022
HUNTSMAN CANCER CENTER
Very impressed by the PA and the physician. They took time to explain everything and was so patient and kind
UofU Patient
July 23, 2022
HUNTSMAN CANCER CENTER
Very pleased
UofU Patient
June 25, 2022
HUNTSMAN CANCER CENTER
Dr Hyngstrom and Brittany saved my life. It's just that simple. I owe them my life.
UofU Patient
April 29, 2022
HUNTSMAN CANCER CENTER
It's been an incredible experience. I feel all the Doctors & nurses are the best of the best at the Huntsman!
UofU Patient
April 18, 2022
HUNTSMAN CANCER CENTER
Everything was answered to my satisfaction
UofU Patient
March 26, 2022
HUNTSMAN CANCER CENTER
Experience was great
UofU Patient
March 26, 2022
HUNTSMAN CANCER CENTER
10 plus on my list
UofU Patient
March 19, 2022
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
March 17, 2022
HUNTSMAN CANCER CENTER
Dr. Hyngstrom not only knows his stuff, he is pleasant to work with.
UofU Patient
March 13, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
March 12, 2022
HUNTSMAN CANCER CENTER
Anything that I could say is positive. Was interested and explained everything.
UofU Patient
February 18, 2022
HUNTSMAN CANCER CENTER
Went down there with one melanoma on my left shoulder got 3 d anda dye injection Dr took out 2lymph knodes and one out side pre cancer doing good now. Thanks to all Dr. Nurses & p.a. And other specialist .
UofU Patient
January 31, 2022
HUNTSMAN CANCER CENTER
They are all great
UofU Patient
December 18, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom is God-sent! As I navigate multiple surgeries with Metastatic Melanoma, the confidence I have in Dr. Hyngstrom's concern & expertise for me is exceptional. Having such a high level of care gives me hope & provides peace, heart & mind, for my journey with such a deadly cancer. Dr. Hyngstrom is a true blessing!
UofU Patient
December 06, 2021
HUNTSMAN CANCER CENTER
Very helpful best place ever
UofU Patient
December 01, 2021
HUNTSMAN CANCER CENTER
I had a lot of questions, some of them a bit complicated, and he took the time to answer them.
UofU Patient
November 25, 2021
HUNTSMAN CANCER CENTER
Follow up already planned
UofU Patient
November 11, 2021
HUNTSMAN CANCER CENTER
Great
Dr. Hyngstrom is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the department of Surgery at the University of Utah. His medical practice is in general surgical oncology with a focus on melanoma and sarcoma, treating patients at the Huntsman Cancer Institute. His research interests include immunotherapy clinical trial development and survivorship issues in cancer patients. He currently serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on improving care for patients with advanced melanoma and other solid tumors. He is co-director of the physician-lead Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI. He also serves as the Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.
Dr. Hyngstrom earned his Bachelor of Arts degree from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from the University of Chicago Pritzker School of Medicine and completed his general surgery residency at the University of Chicago Medical Center. During his residency, he completed a two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. After finishing his general surgery training, Dr. Hyngstrom obtained his fellowship training in general surgical oncology at the University of Texas MD Anderson Cancer Center. Since 2012, he has worked as a faculty surgeon at the University of Utah Huntsman Cancer Institute, and as a contracted surgeon at Intermountain Medical Center.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Surgery
-
Associate Professor (Clinical) |
| Academic Divisions | General Surgery |
| Board Certification | American Board of Surgery |
Education History
| Fellowship | The University of Texas MD Anderson Cancer Center Surgical Oncology, Program Director: Jason Fleming, MD Fellow, 2012 |
| Residency | University of Chicago Medical Center, the Pritzker School of Medicine General Surgery, Program Director: Mitchell Posner, MD Resident, 2010 |
| Fellowship | National Cancer Institute, Surgery Branch Surgical Oncology Clinical Research, Program Director: Steven Rosenberg, MD PhD Fellow, 2007 |
| Professional Medical | The University of Chicago Pritzker School of Medicine Medicine M.D., 2003 |
| Undergraduate | Washington University Biology and History B.A., 1999 |
Selected Publications - Journal Articles
Journal Article
- Adams AM, Carpenter EL, Clifton GT, Vreeland TJ, Chick RC, OShea AE, McCarthy PM, Kemp Bohan PM, Hickerson AT, Valdera FA, Tiwari A, Hale DF, Hyngstrom JR, Berger AC, Jakub JW, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries MB, Peoples GE (2022). Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial. Cancer Immunol Immunother.
- Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H (2022). Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol, JCO2200343.
- Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, Carac C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, ODonoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB (2022). Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg, 157, 835-842.
- Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, Anderson A, Chan E, Faries M, Ross MI (2021). Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med, 27(10), 1789-1796.
- Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, OShea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE (2021). Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Res, 31(4), 378-388.
- Walker HR, Evans E, Nirula R, Hyngstrom J, Matsen C, Nelson E, Pickron B, Zurbuchen E, Morrow EH (2021). "I need to have a fulfilling job": A qualitative study of surgeon well-being and professional fulfillment. Am J Surg, 223(1), 6-11.
- Chick RC, Faries MB, Hale DF, Kemp Bohan PM, Hickerson AT, Vreeland TJ, Myers JW 3rd, Cindass JL, Brown TA 2nd, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Clifton GT, Park H, Sloan AJ, Wagner T, Peoples GE (2021). Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Cancer Med, 10(13), 4302-4311.
- Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559.
- Bleicher J, Asare EA, Flores S, Bowles TL, Bowen GM, Hyngstrom JR (2020). Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study. Am J Surg, 221(4), 844-849.
- Bleicher J, Cohan JN, Huang LC, Peche W, Pickron TB, Scaife CL, Bowles TL, Hyngstrom JR, Asare EA (2020). Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature. World J Gastroenterol, 27(3), 267-280.
- Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, Bowles TL, Hyngstrom JR (2020). Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. J Surg Oncol, 122(8), 1770-1777.
- Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011.
- Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL (2019). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Melanoma Res, 30(2), 173-178.
- Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 59(4), 434-437.
- Park SH, Kwon OS, Park SY, Weavil JC, Hydren JR, Reese V, Andtbacka RHI, Hyngstrom JR, Richardson RS (2020). Vasodilatory and vascular mitochondrial respiratory function with advancing age: evidence of a free radically mediated link in the human vasculature. Am J Physiol Regul Integr Comp Physiol, 318(4), R701-R711.
- Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med, 8(18), 7637-7643.
- Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol, 79(2), 238-244.
- Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.
- Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399.
- Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA (2014). Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol, 109(7), 652-8.
- Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN (8/23/2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res, 23(4), 290--7.
- Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang GJ (2012). Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol, 19(9), 2814-21.
Case Report
Letter
- Bilimoria KY, Russell MC, Hyngstrom J (2017). Melanoma Sentinel-Node Metastasis. [Letter to the editor]. N Engl J Med, 377(9), 891.
- Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D (2014). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. [Letter to the editor]. J Am Acad Dermatol, 71(4), 835-8.
Other
- Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ (2021). Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer (9(10)). England.
- Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN (2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res (23(4), pp. 290-7). England.